A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes

A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes

This Phase 2 study will asses the LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with type 2 diabetes.

Inclusion Criteria:

• Diagnosis of type 2 diabetes meeting all of the following:
• Minimum 6 month history of diabetes prior to screening visit;
• Fasting C-peptide ≥ 0.8 ng/mL at screening visit;
• HbA1C at screening visit 7-10%;
• Fasting glucose from 140-270 mg/dL on Day -7 following washout of all glucose regulating drugs and supplements.
• BMI at screening visit from 25-35 kg/m2;
• LDL-C at screening ≥ 100 mg/dL